JP2013063090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013063090A5 JP2013063090A5 JP2012282502A JP2012282502A JP2013063090A5 JP 2013063090 A5 JP2013063090 A5 JP 2013063090A5 JP 2012282502 A JP2012282502 A JP 2012282502A JP 2012282502 A JP2012282502 A JP 2012282502A JP 2013063090 A5 JP2013063090 A5 JP 2013063090A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- cell
- antibody
- agent
- response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 33
- 210000004027 cell Anatomy 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims 14
- 229930195729 fatty acid Natural products 0.000 claims 14
- 239000000194 fatty acid Substances 0.000 claims 14
- 150000004665 fatty acids Chemical class 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 10
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 10
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 10
- 210000004413 cardiac myocyte Anatomy 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000001590 oxidative effect Effects 0.000 claims 8
- 231100000331 toxic Toxicity 0.000 claims 8
- 230000002588 toxic effect Effects 0.000 claims 8
- 231100000419 toxicity Toxicity 0.000 claims 8
- 230000001988 toxicity Effects 0.000 claims 8
- 206010048610 Cardiotoxicity Diseases 0.000 claims 5
- 231100000259 cardiotoxicity Toxicity 0.000 claims 5
- 229960000575 trastuzumab Drugs 0.000 claims 5
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77709606P | 2006-02-27 | 2006-02-27 | |
| US60/777,096 | 2006-02-27 | ||
| US82123006P | 2006-08-02 | 2006-08-02 | |
| US60/821,230 | 2006-08-02 | ||
| US82737206P | 2006-09-28 | 2006-09-28 | |
| US60/827,372 | 2006-09-28 | ||
| US82834506P | 2006-10-05 | 2006-10-05 | |
| US60/828,345 | 2006-10-05 | ||
| US86773606P | 2006-11-29 | 2006-11-29 | |
| US60/867,736 | 2006-11-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008556587A Division JP5539653B2 (ja) | 2006-02-27 | 2007-02-27 | 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013063090A JP2013063090A (ja) | 2013-04-11 |
| JP2013063090A5 true JP2013063090A5 (cg-RX-API-DMAC7.html) | 2013-10-24 |
Family
ID=38459790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008556587A Expired - Fee Related JP5539653B2 (ja) | 2006-02-27 | 2007-02-27 | 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 |
| JP2012282502A Pending JP2013063090A (ja) | 2006-02-27 | 2012-12-26 | 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008556587A Expired - Fee Related JP5539653B2 (ja) | 2006-02-27 | 2007-02-27 | 細胞脂肪を減少させるため、心毒性を予測するため、チロシンキナーゼ阻害剤による処置による組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8709738B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1996939B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5539653B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101390625B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101438155B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007220094B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2643846A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2475162T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL193715A (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ594178A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007101191A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010036910A1 (en) * | 2008-09-26 | 2010-04-01 | Yoshikazu Ohta | Heart protection by administering an amp-activated protein kinase activator |
| WO2015027171A1 (en) * | 2013-08-23 | 2015-02-26 | Quintiles Transnational Corporation | Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway |
| WO2015148832A1 (en) | 2014-03-27 | 2015-10-01 | Salk Institute For Biological Studies | Compositions and methods for treating type 1 and type 2 diabetes and related disorders |
| CA2977520A1 (en) * | 2015-02-27 | 2016-09-01 | Salk Institute For Biological Studies | Reprogramming progenitor compositions and methods of use therefore |
| WO2017205511A1 (en) | 2016-05-25 | 2017-11-30 | Salk Institute For Biological Studies | Compositions and methods for organoid generation and disease modeling |
| JP7032723B2 (ja) * | 2017-07-21 | 2022-03-09 | 公立大学法人福島県立医科大学 | 薬剤の心毒性評価方法及びそのための試薬又はキット |
| WO2019084395A1 (en) | 2017-10-27 | 2019-05-02 | University Of Virginia Patent Foundation | COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION |
| TWI711458B (zh) * | 2019-07-08 | 2020-12-01 | 大江生醫股份有限公司 | 植物發酵物及其製備方法與用於胃臟保健的用途 |
| KR102493664B1 (ko) | 2020-01-29 | 2023-02-01 | 한국화학연구원 | 심장 독성 예측 모델링 시스템 및 모델링 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9618420D0 (en) * | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| DE60233743D1 (de) * | 2001-09-24 | 2009-10-29 | Lipomics Technologies Inc | Verfahren zur verwendung von quantitativen lipidmetabolondaten |
| SG152922A1 (en) | 2002-11-04 | 2009-06-29 | Univ California | Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body |
| DE602004015626D1 (de) * | 2003-08-28 | 2008-09-18 | Ipsogen | Bei brustkrebs |
-
2007
- 2007-02-27 EP EP07757542.1A patent/EP1996939B1/en not_active Not-in-force
- 2007-02-27 WO PCT/US2007/062871 patent/WO2007101191A2/en not_active Ceased
- 2007-02-27 US US12/280,893 patent/US8709738B2/en not_active Expired - Fee Related
- 2007-02-27 JP JP2008556587A patent/JP5539653B2/ja not_active Expired - Fee Related
- 2007-02-27 NZ NZ594178A patent/NZ594178A/xx not_active IP Right Cessation
- 2007-02-27 CA CA002643846A patent/CA2643846A1/en not_active Abandoned
- 2007-02-27 ES ES07757542.1T patent/ES2475162T3/es active Active
- 2007-02-27 CN CN2007800136974A patent/CN101438155B/zh not_active Expired - Fee Related
- 2007-02-27 AU AU2007220094A patent/AU2007220094B2/en not_active Ceased
- 2007-02-27 CN CN2013101368247A patent/CN103217520A/zh active Pending
- 2007-02-27 KR KR1020087023650A patent/KR101390625B1/ko not_active Expired - Fee Related
- 2007-02-27 NZ NZ571465A patent/NZ571465A/en not_active IP Right Cessation
-
2008
- 2008-08-26 IL IL193715A patent/IL193715A/en not_active IP Right Cessation
-
2012
- 2012-12-26 JP JP2012282502A patent/JP2013063090A/ja active Pending
-
2013
- 2013-04-05 US US13/857,591 patent/US20130288285A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013063090A5 (cg-RX-API-DMAC7.html) | ||
| JP2011037847A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0811490A2 (pt) | Método colorimétrico e estojo de detecção de sequências específicas de ácidos nucléicos através de nanopartículas metálicas funcionalizadas com oligonucleotídos modificados. | |
| EP2576837A4 (en) | CIRCULATING NUCLEIC ACID BIOMARKERS ASSOCIATED WITH PROSTATE CANCER | |
| EP2867866A4 (en) | METHOD AND SYSTEMS FOR AUTOMATED PARKING OF VEHICLES WITH CONTROLLING | |
| WO2012174282A3 (en) | Biomarker compositions and methods | |
| JP2017522908A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0715346A2 (pt) | Detecção de analitos e ácidos nucléicos | |
| WO2011094535A3 (en) | Biomarkers of aging for detection and treatment of disorders | |
| FR2958161B1 (fr) | Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une emulsion directe contenant un agent alcalin | |
| IL225646A0 (en) | Methods and kits for detecting cancer cells in the circulation of pancreatic patients using polyspecific capture and cocktail detection reagents | |
| EP2394163A4 (en) | PROCEDURE FOR DETECTION OF THE JC POLYOMAVIRUS | |
| WO2013050881A3 (en) | Direct nucleic acid analysis | |
| JP2014527400A5 (cg-RX-API-DMAC7.html) | ||
| WO2013066369A3 (en) | Methods for detecting graft-versus-host disease | |
| WO2012112315A3 (en) | Methods for diagnosis of kawasaki disease | |
| CL2013003433A1 (es) | Método para analizar una muestra biológica de un sujeto con cáncer que comprende determinar un nivel de expresión de los biomarcadores gli-1, otx-2, shroom2, pdlim3, y sphk1 en dicha muestra, en donde el nivel de expresión de los biomarcadores en coparación con un control, proporciona un indicador de diagnóstico de si el sujeto tiene una probabilidad aumentada de respuesta a: un ácido metil-4’-trifluorometoxi-bifenil-3-carboxílixo [6-(cis-2,6-dimetil-morfolino-4-il)-piridin-3-il]-amida, ó 2-[(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2’] bipirizanil-5’-il]-propan-2-ol; método para seleccionar a un sujeto que tiene cáncer para el tratamiento con uno de dichos compuestos, el cual comprende determinar el nivel de expresión de shroom2 o sphk1, en una muestra biológica del sujeto. | |
| BRPI0911863A2 (pt) | método para determinar a presença de um analito em uma amostra de estrutura queratinizada de um indivíduo. | |
| EA201390638A8 (ru) | Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения | |
| DE602005010515D1 (de) | Nachweisverfahren für lebenfähige Zellen | |
| JP2018528441A5 (cg-RX-API-DMAC7.html) | ||
| JP2009515556A5 (cg-RX-API-DMAC7.html) | ||
| WO2015048804A3 (en) | Protein biomarker and uses thereof | |
| WO2012142003A3 (en) | Chemical ligation | |
| JP2012118051A5 (cg-RX-API-DMAC7.html) |